Compare Gilead Sciences, Inc. (GILD) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Noble Corporation plc — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while Noble Corporation plc trades at $40.5 (market cap $6.47B). The key difference: Gilead Sciences, Inc. is far larger — about 25.3× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.93%). Which is the better fit depends on your goals.
| GILD | NE | |
|---|---|---|
Market Cap | $163.51B | $6.47B |
Sector | Health | Technology |
52-Week High | $155.80 | $54.37 |
52-Week Low | $108.22 | $25.70 |
Enterprise Value | $178.05B | $7.73B |
Dividend Yield | 2.49% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Noble Corporation (NE) trades at $40.49, down 2.86% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.26, beating expectations, and secured new drilling contracts in Brunei and the UK. Financials show stable revenue around $3.3 billion and improving net margins, with a P/E of 28.38 and EV/EBITDA of 7.3 indicating moderate valuation.
Outlook is cautiously positive with a consensus price target of $49.75, though recent earnings misses and competitive pressures pose risks. The stock offers potential upside from contract wins and operational efficiency, but investors should weigh volatility in energy services demand and execution risks against the 31% analyst buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
